Reata Pharma (RETA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Sales | 2,216 | 11,490 | 9,019 | 26,517 | 53,589 |
| Gross Profit | 2,216 | 11,490 | 9,019 | 26,517 | 53,589 |
| Operating Expenses | 280,250 | 256,198 | 235,344 | 311,737 | 130,467 |
| Operating Income | -278,034 | -244,708 | -226,325 | -285,220 | -76,878 |
| Other Income | -33,892 | -53,128 | -43,914 | -4,942 | -3,642 |
| Pre-tax Income | -311,926 | -297,836 | -270,239 | -290,162 | -80,520 |
| Income Tax | -25 | -450 | -22,487 | 8 | 26 |
| Net Income Continuous | -311,901 | -297,386 | -247,752 | -290,170 | -80,546 |
| Net Income | $-311,901 | $-297,386 | $-247,752 | $-290,170 | $-80,546 |
| EPS Basic Total Ops | -8.54 | -8.19 | -7.35 | -9.54 | -2.91 |
| EPS Basic Continuous Ops | -8.54 | -8.19 | -7.35 | -9.54 | -2.91 |
| EPS Diluted Total Ops | -8.54 | -8.19 | -7.35 | -9.54 | -2.91 |
| EPS Diluted Continuous Ops | -8.54 | -8.19 | -7.35 | -9.54 | -2.91 |
| EPS Diluted Before Non-Recurring Items | N/A | -8.19 | -7.35 | -9.54 | -2.87 |
| EBITDA(a) | $-280,211 | $-236,942 | $-217,644 | $-282,914 | $-75,559 |